Sanofi upgrades 2021 guidance once again – Dupixent drives growth

On Thursday morning, French Sanofi published its report for the third quarter of the year, and in connection with the release, the pharmaceutical company upgrades its earnings-per-share expectations for the full year.

Photo: Charles Platiau/Reuters/Ritzau Scanpix

The French pharmaceutical company Sanofi has upgraded its 2021 financial guidance for earnings per share (business EPS), it reports in a press release on Thursday morning.

Sanofi is now expecting growth of around 14 percent for its business EPS at current exchange rates (CER). The French firm also adjusted its business EPS guidance upward in connection with the second quarterly report of the year. Back then, it reported a new EPS guidance of 12 percent, compared to its previous full-year growth rate of a high single-digit figure.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs